IMAB Company Profile and Key Details
I-Mab
Price Chart
Stock Price Today
I-Mab (IMAB) stock declined over -0.69%, trading at $2.88 on NASDAQ, down from the previous close of $2.90. The stock opened at $2.90, fluctuating between $2.81 and $3.01 in the recent session.
Stock Snapshot
Relevant Articles
SEC Fillings
Current Report (8-k)
| Filing Date | Accepted Date | |
|---|---|---|
Annual Report (10-k)
| Filing Date | Accepted Date | |
|---|---|---|
Stock Price History Chart
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 29, 2025 | 4.70 | 4.77 | 4.49 | 4.63 | 819.7K |
| Oct 28, 2025 | 4.74 | 4.88 | 4.43 | 4.64 | 2.67M |
| Oct 27, 2025 | 4.40 | 4.75 | 4.39 | 4.70 | 1.35M |
| Oct 24, 2025 | 4.40 | 4.49 | 4.13 | 4.22 | 1.36M |
| Oct 23, 2025 | 4.76 | 4.81 | 4.33 | 4.39 | 1.37M |
| Oct 22, 2025 | 5.10 | 5.12 | 4.62 | 4.82 | 924.71K |
| Oct 21, 2025 | 5.26 | 5.33 | 4.97 | 5.13 | 757.75K |
| Oct 20, 2025 | 5.80 | 5.97 | 5.06 | 5.22 | 2.03M |
| Oct 17, 2025 | 6.30 | 6.39 | 4.85 | 5.77 | 4.09M |
| Oct 16, 2025 | 6.15 | 6.79 | 5.95 | 6.56 | 2.56M |
| Oct 15, 2025 | 6.34 | 6.72 | 6.00 | 6.13 | 1.5M |
| Oct 14, 2025 | 5.57 | 6.10 | 5.45 | 6.06 | 2.21M |
| Oct 13, 2025 | 4.87 | 6.16 | 4.76 | 5.79 | 4.59M |
| Oct 10, 2025 | 4.85 | 4.93 | 4.32 | 4.77 | 2.04M |
| Oct 09, 2025 | 5.05 | 5.13 | 4.81 | 4.85 | 1.46M |
| Oct 08, 2025 | 4.43 | 5.55 | 4.40 | 5.07 | 5.67M |
| Oct 07, 2025 | 4.44 | 4.50 | 4.19 | 4.37 | 1.11M |
| Oct 06, 2025 | 4.43 | 4.47 | 3.98 | 4.35 | 2.08M |
| Oct 03, 2025 | 4.34 | 4.51 | 4.26 | 4.32 | 1.97M |
| Oct 02, 2025 | 4.00 | 4.15 | 3.91 | 4.13 | 1.72M |
Contact Details
About Company
I-Mab is a biopharmaceutical company, operating at the clinical stage, dedicated to the discovery, advancement, and commercialization of biologic therapies. Its core mission is to address critical medical needs in both oncology and autoimmune diseases. The company boasts a comprehensive pipeline of drug candidates. Among its most advanced programs, Eftansomatropin alfa, a long-acting human growth hormone, has successfully completed Phase 3 clinical trials for pediatric growth hormone deficiency. Similarly, Lemzoparlimab, a CD47 monoclonal antibody, has concluded its Phase 2 clinical evaluation. Other notable assets include Felzartamab, a CD38 antibody currently undergoing Phase 1b/2a development for membranous nephropathy. Both TJ107 and Efineptakin (a long-acting variant), recombinant human IL-7 therapies, are progressing through Phase 2 for cancer treatment-related lymphopenia and immunotherapy applications. The pipeline further comprises Enoblituzumab, a humanized B7-H3 antibody in Phase 2 for head and neck cancer and other malignancies; Uliledlimab, a CD73 antibody, also in Phase 2 for solid tumors; and TJ210, a monoclonal antibody against human C5aR1, which is in Phase 1 for cancer and autoimmune disorders. I-Mab's portfolio also features Plonmarlimab, a GM-CSF monoclonal antibody intended for inflammation and CRS-related therapies, alongside several specialized oncology agents: TJ-L14B (a PD-L1-based tumor-dependent T-cell engager for solid cancers), TJ-CD4B (a tumor-dependent T-cell engager for gastric and other cancers), TJ-L1IF (a PD-L1/IFN-a antibody-cytokine fusion protein for solid tumors), and TJ-C64B (a tumor-dependent T-cell engager for ovarian and other cancers). To bolster its development efforts, I-Mab has forged strategic alliances with leading industry partners, including AbbVie Ireland Unlimited Company, Sinopharm Group Co. Ltd., PT Kalbe Genexine Biologics, and Roche Diagnostics. Established in 2014, the company's headquarters are located in Shanghai, People's Republic of China.
Company Information
| Employees | 32 |
| Beta | 1.46 |
| Sales or Revenue | $27.64M |
| 5Y Sales Change% | -0.641% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Stock Peers
Company Overview
Technical Performance
Valuation Metrics
Dividend & Fair Value
Earnings & Analyst Outlook
Shareholding & Insider Activity
Financial & Profitability Overview
On valuation metrics, I-Mab trades at a P/E of -59.63, P/S of 0.00 and P/B of 1.20. The current ratio is 22.82 and quick ratio is 22.82. Debt-to-equity is 0.02, supported by a cash flow-to-debt ratio of 0.00.
Quarterly Financial Highlights
The company ended the quarter with $3.45B in cash and short-term investments, a total debt of $74.99M, and net debt of - $3.14B. Total assets were $4.07B, with equity of $3.01B. Financials further reflected weakness, with operating cash flow of - $1.10B, free cash flow of - $1.15B, and capital expenditures of - $45.83M.
Price Forecast & Outlook
Key Takeaways
Frequently Asked Questions
Interim Chief Financial Officer, Chief Operating Officer & Director
Dr. Weiming Tang Ph.D.
Executive Vice President of Global Bus. Devel. & Chief Bus. Officer
Mr. Ivan Yifei Zhu
Chief Commercial Officer
Dr. Jerry Wang
Co-Founder & Chief Scientific Officer
Ms. Gigi Qi Feng
Chief Communications Officer
Mr. Tianyi Zhang
Vice President of Investor Relations
Mr. Raj Kannan
Chief Executive Officer & Director
Dr. Andrew X. Zhu M.D., Ph.D.
Member of Scientific Advisory Board, Pres & Director
Dr. Jingwu Zhang Zang M.D., Ph.D.
Founder & Chairman
Dr. Fernando J. Salle´s Ph.D.
Senior Vice President and Head of U.S. & EU Bus. Devel.
Claire Xu
Head of US site
Mr. Richard L. Yeh CLP, Esq., M.B.A.
Interim Chief Financial Officer, Chief Operating Officer & Director
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep